back to overview


New MTIP investment – Nitinotes Series A Round

March 16, 2018 + Jessica Di Palo
5 Min read

MTIP has invested in Nitinotes Ltd, an Israeli based company developing breakthrough, minimally invasive devices for the multi-billion dollar obesity market.

Nitinotes Logo with the simulation of their product the endozip™

MTIP joins Elron Industries and Accelmed to expand the Series A round, bringing funds raised to $6.7M.

Nitinotes has developed the EndoZipTM, a fully automated, operator independent gastroscopic suturing system, allowing gastroenterologists as well as surgeons to bring a durable solution to their patients. The procedure creates an effect of stomach volume restriction and motility impair – both are needed to help obese patients reducing weight.

“We’ve welcomed MTIP into the round due to their experience in medical device investing and extensive networks in Europe,” said Raz Bar On, CEO of Nitinotes.  “As we enter our first clinical trial, the value MTIP can bring to us in navigating the clinical and regulatory pathways will be very useful.”

Nitinotes has a great team developing a much needed solution for the large number of obese patients that cannot lose weight from just diet and lifestyle change.  said Dr Christoph Kausch Founding Partner and CEO of MTIP.  “Metabolic disease including obesity are creating massive challenges for health care systems across the globe.  We are excited about the potential that Nitinotes has to improve the lives of these patients.”

Bruce Meadows, the Fund’s Senior Investment Director, added that “Nitinotes is great example of the early stage companies we are looking for.  The company is lean, focused on creating vale and is exceptionally managed.”

Share the Article


SFDR Art. 8 or Art. 9? What’s the difference?

SFDR: getting the terminology right


MTIP participates in Oviva’s new $80m Series C funding

Oviva raises $80 million financing round


MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

MTIP's new investment in Intelligencia


Private Equity 101: Part one – Glossary

Are you new to the healthtech space?


Leading brands revolutionize care journeys with Lumeon

How Lumeon orchestrates care journey


Trialbee – our hero in patient matching and recruiting for clinical trials

Trialbee - patient matching and recruiting

news blog

Digital healthcare: patient-first?

Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

New SFDR obligations


MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation

First Closing of Fund II


How to pitch to a healthtech Investor

Blog Pitching


MTIP invests in Koa Health to make mental health treatment more accessible

New investment in Koa Health


MTIP scored fantastic grades in the UNPRI assessment report of 2020

UNPRI Report grades 2020


4 Health VCs Share Their Business Priorities and What is Next

Interview Techtour


MTIP invests in Trialbee

New investment in Trialbee


TytoCare closes $50 million round as the demand for telehealth accelerates

TytoCare closes new round


The digital healthtech sector is expanding – and so are we!

Two new empolyees start in April


MTIP has sucessfully exited Blueprint Genetics

Blueprint exit January 2020


New MTIP investment in Oviva

New investment in Oviva


Whitepaper: A positive prognosis for the future of healthtech

Our first Whitepaper


Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch

Elite Summit 2019


MTIP Healthcare Clinic 2019

Healthcare clinic 2019

New MTIP investment in Cynerio

New investment in Cynerio


MTIP invests in Lumeon Ltd.

New investment in Lumeon

Magenverkleinerung mit der Handnähmaschine

Nitinotes news paper article


New MTIP investment in Quanta Dialysis Technologies

New investment in Quanta